GT Biopharma (NASDAQ:GTBP) Research Coverage Started at Roth Mkm

Roth Mkm began coverage on shares of GT Biopharma (NASDAQ:GTBP) in a research note issued to investors on Monday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $11.00 price objective on the stock.

GT Biopharma Price Performance

Shares of GTBP opened at $2.74 on Monday. GT Biopharma has a one year low of $1.92 and a one year high of $10.66. The business’s 50 day simple moving average is $2.69 and its 200-day simple moving average is $2.73.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.